Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nimodipine
Drug ID BADD_D01569
Description Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Indications and Usage For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
Marketing Status Prescription; Discontinued
ATC Code C08CA06
DrugBank ID DB00393
KEGG ID D00438
MeSH ID D009553
PubChem ID 4497
TTD Drug ID D0XN1F
NDC Product Code 49452-4854; 62559-210; 58159-047; 43898-0117; 63739-797; 62973-100; 10888-8113; 58624-0495; 67877-297; 81624-660; 24338-230; 23155-512; 70966-0012; 76055-0047; 24338-260; 68084-912; 10888-8124; 69452-209
Synonyms Nimodipine | Bay e 9736 | e 9736, Bay | Brainal | Calnit | Kenesil | Nymalize | Nimodipin Hexal | Hexal, Nimodipin | Nimodipin-ISIS | Nimodipin ISIS | Nimodipino Bayvit | Bayvit, Nimodipino | Nimotop | Remontal | Admon | Modus
Chemical Information
Molecular Formula C21H26N2O7
CAS Registry Number 66085-59-4
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Anaemia01.03.02.001--
Blood glucose increased13.02.02.002--Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Blood pressure decreased13.14.03.002--Not Available
Bradycardia02.03.02.002--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.002--
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Electrocardiogram abnormal13.14.05.001--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Haematoma24.07.01.001--
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages